Strs Ohio Takes $27,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Strs Ohio acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 800 shares of the specialty pharmaceutical company’s stock, valued at approximately $27,000.

Other hedge funds have also recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $34,000. Eagle Bay Advisors LLC grew its holdings in shares of Supernus Pharmaceuticals by 143.0% during the second quarter. Eagle Bay Advisors LLC now owns 2,663 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 1,567 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Supernus Pharmaceuticals by 163.3% during the first quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 1,850 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Supernus Pharmaceuticals by 28.4% during the second quarter. Nisa Investment Advisors LLC now owns 3,390 shares of the specialty pharmaceutical company’s stock worth $98,000 after purchasing an additional 750 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 71.6% during the second quarter. Lazard Asset Management LLC now owns 3,498 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,460 shares during the last quarter. 99.82% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 1,115 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $35.00, for a total value of $39,025.00. Following the sale, the chief executive officer now owns 780,742 shares of the company’s stock, valued at $27,325,970. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, VP Padmanabh P. Bhatt sold 6,800 shares of the business’s stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the sale, the vice president now owns 1,644 shares of the company’s stock, valued at $57,457.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Jack A. Khattar sold 1,115 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $35.00, for a total transaction of $39,025.00. Following the completion of the sale, the chief executive officer now directly owns 780,742 shares in the company, valued at approximately $27,325,970. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,340 shares of company stock valued at $2,629,303. Company insiders own 7.99% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $40.31 on Monday. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of 62.98 and a beta of 0.94. Supernus Pharmaceuticals, Inc. has a 52 week low of $24.95 and a 52 week high of $41.19. The firm’s 50-day simple moving average is $36.76 and its two-hundred day simple moving average is $34.33.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last announced its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.29). The company had revenue of $177.35 million during the quarter, compared to the consensus estimate of $173.22 million. Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

SUPN has been the topic of several analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 13th. Piper Sandler cut their price target on shares of Supernus Pharmaceuticals from $38.00 to $36.00 in a report on Tuesday, October 11th.

Supernus Pharmaceuticals Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Further Reading

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.